Comments from DRG's Business Insights Analyst, Kerri Brown, M.Pharm.:
- "The hemophilia A landscape will start to look very different from 2019, with the launch of some innovative agents like Roche / Chugai's ACE-910 and Alnylam's fitusiran and following on from these, the hemophilia A gene therapies. These new agents have an opportunity to make a big impact on the adherence rate and clinical outcomes achievable for severe hemophilia A patients, who are still largely undertreated today.
- "The extended half-life factor IX products are here to stay, and they will make it difficult for new hemophilia B products to gain market share"
- "Effective treatment options for the hemophilia inhibitor population are eagerly awaited. We expect ACE-910 and CSL-689 to go a long way to address this large unmet need, and will make prophylactic treatment a reality for inhibitor patients."
Follow DRG on Twitter @DRGInsights and on LinkedIn and keep up with the latest industry news on the DRG Blog.
About Decision Resources Group
DRG, a subsidiary of Piramal Enterprises Ltd., offers best-in-class, high-value data, analytics and insights products and services to the healthcare industry, delivered by more than 1000 employees across 17 offices in North America, Europe and Asia. DRG provides the Life Sciences, Provider, Payer and Financial Services industries the data, tools, insights and advice they need to compete and thrive in an increasingly complex and value-based marketplace. decisionresourcesgroup.com.
Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/drg-forecasts-new-treatment-options-will-revolutionize-the-management-of-hemophilia-a-and-hemophilia-with-inhibitors-hemophilia-b-patients-are-relatively-well-served-300371262.html
SOURCE Decision Resources Group